CYP19A1 and breast cancer: <h4>Objective</h4>Breast cancer survivors undergoing hormonal therapy with aromatase inhibitors face a significantly increased risk of developing musculoskeletal pain, leading to treatment discontinuation rates of 13% to 22%.